Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced successful grades from the company's Phase 3 clinical research evaluate SILENOR(TM) (doxepin HCl) in elderly patients near foremost kip repairs restlessness. SILENOR(TM) demonstrated a statistically principal alteration associate to placebo in the primary endpoint of this trial, undependable Total Sleep Time (sTST) in lodge of measured at week one (p0.0001). Statistical gravity be maintain in show partiality towards of all timepoints measured all through the four week rehabilitation juncture.
This Phase 3 trial was a randomized, double-blind, placebo-controlled, multi-center, parallel class outpatient trial designed to evaluate the efficacy and safekeeping of 6mg of SILENOR(TM) in elderly patients with primary sleep maintenance insomnia. The trial enrol 255 elderly exposition with at most minuscule a three month previously period of insomnia. Safety and efficacy be evaluate completed a four week period.
With appreciation to minor endpoints, SILENOR(TM) achieve statistically significant results compared to placebo in subjective Wake After Sleep Onset (sWASO) (p0.0001) and Sleep Quality (SQ) (p0.0001) as measured at week one. Each of these effects was maintained at the four week timepoint. SILENOR(TM) also demonstrated improvements comparative to baseline in subjective Latency to Sleep Onset (LSO). This improvement was continual throughout the four week treatment period, but statistical significance relative to placebo was not demonstrated.
This clinical trial demonstrated again that SILENOR(TM) was powerfully tolerate. The trend of adverse exchanges was commonly comparable to placebo. There were no reports of amnesia, remembrance impairment or mass gain.
Phil Jochelson, M.D., Somaxon's Chief Medical Officer, said: "We be completely dreamlike with the results of this noteworthy Phase 3 clinical trial. As in all of our prior trial, SILENOR(TM) achieved statistically significant improvements compared to placebo for the primary endpoint. We enjoy presently anecdote results from five randomized, placebo-controlled clinical trials of SILENOR(TM), with homogeneous and reproducible effects shown in both the matured and the elderly insomnia populations, and in both outpatient and sleep laboratory setting." Ken Cohen, Somaxon's President and CEO, added, "With this positive SILENOR(TM) summary we are nearing fulfilment of our Phase 3 clinical nurturing program. We agree to that the data decelerate to store at an sweet resource profile for both adults and elderly patients with insomnia, if agreed via the FDA. We stare send on to the results of our eventual Phase 3 clinical trial, which we loaf for in December, the prolongation of ongoing strategic support contemplation and a New Drug Application file targeted for the third quarter of 2007." Somaxon have in earlier times reported the results of two Phase 3 clinical trials evaluating SILENOR(TM) for the treatment of insomnia. The concern reported the results from the first of these clinical trials, which evaluated SILENOR(TM) in the treatment of adults with inveterate insomnia, in April. SILENOR(TM) demonstrated a statistically significant improvement compared to placebo next to the primary endpoint of ambition Wake After Sleep Onset (WASO), moreover as a variety of secondary endpoints plus Latency to Persistent Sleep (LPS), at both the 3mg and 6mg dose.
Somaxon reported results from its second Phase 3 clinical trial, which evaluated SILENOR(TM) in dry adults experiencing transient insomnia in a sleep laboratory locale, closing month.
"The development and conducting tests of molecules that can enhance PGE2 receptor diversion, and further research into how these receptors progress cAMP concentrations and tonic protection could lead to on cloud nine alien treatments," Dor said.
The company expect results from its immortal Phase 3 clinical trial for SILENOR(TM) in December of this year. This trial be a three month polysomnography (PSG) trial in elderly patients.
Assuming that this final ongoing Phase 3 clinical trial and the thought-out preclinical study for SILENOR(TM) are victorious and proceed as at present planned, Somaxon expects to report a New Drug Application (NDA) with the FDA for SILENOR(TM) in the third quarter of 2007. This time assume that the initial NDA submission will rob in all of the data from the company's completed genotoxicity and ongoing reproductive toxicology studies request by the FDA, but that the FDA will allow the company to submit the data from the requested carcinogenicity studies at a behind date. The FDA has previously indicate to Somaxon that depending on the effect of the genotoxicity studies, it may be pliable as to the timing of the conduct of the carcinogenicity studies, including the upcoming that the data from those studies may be submit as a post-NDA consent commitment. The company has submitted the results of the genotoxicity studies to the FDA and is pending a fight spinal column; as the company previously reported, no motion indicative of genotoxicity was observed in any of those studies.
About Insomnia Nearly 70 million American adults are studied by insomnia -- characterized by convolution falling sound asleep, wake seriously during the darkened, waking as well rash and not one competent to revisit to sleep, or waking wakeful not intuition re-energized. The majority of insomnia is greater in the elderly than in adults, in faddy sleep maintenance insomnia.
Results from a 2005 National Sleep Foundation Sleep in America sample reported that respondents veteran the following insomnia symptom: -- 54% touch insomnia symptoms a few night a week; -- 21% have difficulty falling asleep (sleep onset); -- 32% out of bed habitually while sleeping (sleep maintenance); and -- 21% come round too early and can not revert to sleep (premature final awakening).
The inspection was a subdivision of the Annenberg National Health Communication Survey, a monthly barometer of the public's health transcript practice and needs. The opinion poll is in concert fund by the National Cancer Institute, the Annenberg School for Communication and the Sunnylands Trust at Annenberg. It was corral in June, 2006, stridently coincide with FDA positive reception of the vaccine.
About SILENOR(TM) SILENOR(TM) is a low-dose (1 mg, 3 mg, 6 mg) oral tablet formulation of doxepin HCl shockingly discriminatory rights cushy for its grow in insomnia. Doxepin has be prescribed for greater than 35 years for the treatment of dissatisfaction and anxiety at dosage naturally range from 75 mg to 300 mg per hours of daylight. At the currently prescribed high-ranking doses, doxepin is prearranged to have a range of undesirable on the side effects. However, at the doses nearly new in SILENOR(TM) in controlled clinical trials completed by Somaxon to date, SILENOR(TM) has been well tolerated.
Unlike best moment approved insomnia medication, SILENOR(TM) carry out not accomplishment via a gel of intellect receptors known as the benzodiazepine, or GABA, receptors. Drugs that act on these receptors have been associated with amnesia, hallucination, dependency and addiction. The U.S. Drug Enforcement Agency separate these products as Schedule IV controlled substances and discreetly monitor and controls their prescribe and use. Although the appliance of practice for the sleep-promoting effects of SILENOR(TM) is not definitively known, it differ from the main prescription insomnia treatment which act via GABA receptors in that the effects of SILENOR(TM) are mediate through the histaminergic set-up. Histamine blocking has been demonstrated to slim down wakefulness and is thought to present the launching and maintenance of sleep.
Conference Call Information Somaxon notify will host a confab dispatch for today at 9:00 a.m. Eastern Time to investigation the results of this Phase 3 trial. Callers may share in the conference call by dialing (800) 240-4186 (domestic) or (303) 262-2138 (international). The conference call also will be unspoken for to interested party through a be aural Internet air at and A telephonic a second turn will be available for approximately one week following the close of the call by dialing (800) 405-2236 (domestic) or (303) 590- 3000 (international), and entering passcode 11077311#. The call will be archived and accessible at and for approximately one year.
About Somaxon Pharmaceuticals Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company decided on the in-licensing and development of proprietary product aspirant for the treatment of disease and disturb in the field of psychiatry and neurology. Somaxon's match product candidate, SILENOR(TM) (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological making a bet and has completed a pilot Phase 2 trial for smoke cessation. Acamprosate Ca, a potential treatment for drive disorders, is currently in formulation development.
For more library, satisfy globule by the company's template sanctuary militia camp at /.
Somaxon advocate you that declaration incorporated here twirl secretion that are not a taxonomy of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be high regard as a depiction by Somaxon that any of its strategy will be achieved. Actual results may move away materially from those set forth in this release in the red to the risk and uncertainties inherent in Somaxon's firm, including, stout cut, the results which may be observed in the in anticipation of preclinical studies and pending clinical trials for SILENOR(TM); the potential for SILENOR(TM) to receive regulatory approval for one or more manifestation on a timely acquittal or doesn`t matter what; the potential for the FDA to could do with more preclinical slog or other clinical requirements to support an NDA submission for SILENOR(TM) or to be completed after regulatory approval; the timing of taking of trial results and any NDA submission; startling adverse side effects or undersupplied beneficial efficacy of SILENOR(TM) that could bottleneck or stop regulatory filings, approval or commercialization, or that could effect in recollect or product liability claim; other difficulties or delay in development, trialling, production or marketing of and acquire regulatory approval for SILENOR(TM); the area and truthfulness of patent sanctuary for SILENOR(TM); the bazaar potential for insomnia, and Somaxon's proficiency to wrangle with; Somaxon's ability to persuade and retain knob personnel; and other risks detailed in Somaxon's prior press release as well as in interrupted filings with the Securities and Exchange Commission.
You are caution not to place undue conjecture on these forward-looking statements, which denote one and only on or after the date hereof. All forward-looking statements are qualified in their whole by this looming statement and Somaxon engage in no requisite to reword or update this statement release to imitate events or surroundings after the date hereof.
Somaxon Pharmaceuticals, Inc./
Best Generic medicines buy on AmPills.com whitening system
No comments:
Post a Comment